Considering the dual roles played by IL-6 on insulin sensitivity in diverse tissues and that these effects depend on different times of exposition and signaling pathways, further studies are necessary to ensure the safety of blocking IL-6 pathways as a pharmacological target to treat diabetes. This evidence concerns the gene INS and diabetes mellitus.